TCR2 Therapeutics Inc. (TCRR) Stock Analysis
DELISTED 2023
What happened to TCR2 Therapeutics Inc. (TCRR) stock?
TCR2 Therapeutics Inc. (TCRR) no longer trades on public markets. It was delisted in May 2023. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- May 2023
- Last recorded price (historical):
- $1.48 (last quote on record before the May 2023 delisting; historical, not a current quote)
Market cap $58.1M is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
TCR2 Therapeutics Inc. (TCRR). TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company focused on developing novel T cell receptor (TCR) therapies for cancer patients. Their lead product, gavo-cel, targets mesothelin-positive solid tumors and is currently in Phase I/II clinical trials.
Last analyzed: May 10, 2026TCR2 Therapeutics Inc. (TCRR) Healthcare & Pipeline Overview
More about this archive record
Can I still buy TCRR shares?
No. TCRR stopped trading on public markets in May 2023, so the shares are not available through a broker. Anything you see quoted for TCRR elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before TCRR stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to TCR2 Therapeutics Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.